Lisinopril activates BI1 to reprogram lipid metabolism and restore autophagy in ALS
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Amyotrophic lateral sclerosis (ALS) involves disrupted lipid metabolism. Bax inhibitor 1 (BI1), an endoplasmic reticulum protein downregulated in ALS neuroprotective, represents a therapeutic target, but its metabolic regulatory mechanisms are incompletely understood. Using transcriptomics in skeletal muscle of ALS mice pre- and post-BI1 treatment, we identified BI1-regulated pathways. Structure-based virtual screening of FDA-approved compounds nominated lisinopril as a BI1 activator. Lisinopril upregulated BI1 protein expression, stabilizing mitochondrial membrane potential and protecting against SOD1G93A-induced apoptosis in NSC34 cells. Concurrently, it regulated TGF-β1/mTOR-dependent autophagy, maintained NMJ integrity, and reshaped triglyceride/sphingolipid/glycerophospholipid metabolism to attenuate spinal cord pathology in ALS mice, promoting energy metabolism shift toward glucose oxidation. Additionally, lisinopril inhibited the TGF-β1/Smad2/3 pathway to alleviate muscle fibrosis, downregulate Acp5/FN expression, and reduce type I collagen deposition. In conclusion, this study provides evidence that pharmacological activation of BI1 by lisinopril suppresses TGF-β1, modulates lipid metabolism, and ameliorates ALS pathology, demonstrating promising therapeutic repurposing potential. Lisinopril is identified as a BI1 activator that counteracts ALS pathology. It remodels lipid metabolism, restores autophagic flux via TGFβ1/mTOR signaling, and mitigates fibrosis. This multi-target mechanism supports the therapeutic repurposing of lisinopril for ALS.
Fields of Study & Subjects
Amyotrophic Lateral Sclerosis Research
Alzheimer's disease research and treatments
Muscle Physiology and Disorders
Publication details
- Journal / source
- Communications Biology
- Volume
- 9
- Issue
- 1
- Pages
- 705
- Publication date
- 31 March 2026
- Language
- EN